ecubectedin

Ecubectedin (PM14) is a novel small molecule antitumor agent under clinical investigation for the treatment of advanced solid tumors. It is structurally related to the ecteinascidin family (which includes trabectedin and lurbinectedin). Ecubectedin acts as a transcriptional inhibitor by forming DNA adducts that specifically inhibit RNA synthesis and block active transcription of protein-coding genes. This mechanism leads to potent antiproliferative activity in various human solid cancer models both in vitro and in vivo. The drug has demonstrated antitumor effects across multiple tumor types, including soft tissue sarcoma, ovarian, pancreatic, prostate, lung, kidney, gastric, breast, and renal cancers. Clinical trials are ongoing to determine its safety profile and optimal dosing when administered intravenously[3][4][5][7].

Other names

ecubectedinPM14PM-14PM 14